← Home / Enliven Therapeutics, Inc. (ELVN)
Stock Analysis
Enliven Therapeutics, Inc. (ELVN)
ELVN
ELVN · Market data
53.95 +1.85%
Track ELVN in your personal workspace Monitor performance, SPY relative strength and WOI View from your watchlist.
Alert me when ELVN price is:
52W Range Position
99%
LOWMIDHIGH
Trend
Constructive
Momentum
Neutral
Updated: 2026-07-31 11:46 UTC
WOI Investment Thesis
Constructive
Confirmation improves above 54.33. Holding above 47.80 keeps the current thesis intact.
⚖️
✓
Fundamentals
Insufficient / Insufficient
✓
Price Structure
Constructive
•
Momentum
Neutral
×
Breakout Confirmation
Pending
Risk Level
Moderate
Analysis Scope
1Y Daily
Key Decision Levels
✓
Hold Above
Structure remains valid above support.
47.80
↗
Break Above
Confirmation improves above resistance.
54.33
🎯
Next Objective
Pattern-derived target if setup continues.
—
×
Thesis Break
Scenario weakens below invalidation.
Below 47.80
Recent Company Events
SEC VERIFIED
Latest material filings
JUN
12
●
Material Agreement
MEDIUM
ELVN material agreement
On June 11, 2026, Enliven Therapeutics, Inc.
8-K Filing • SEC EDGAR
MAY
7
●
Financial Results
HIGH
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update
Phase 1 data update for ELVN-001 expected mid-2026 Initiation of the Phase 3 ENABLE-2 pivotal trial of ELVN-001 expected in the second half of 2026 Strong balance sheet with $452 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into the first half of 2029 BOULDER,...
8-K Filing • SEC EDGAR
What's Driving ELVN?
📈 Technical recovery is improving
Momentum is Neutral. Watch 54.33 for confirmation and 47.80 for structure risk.
💼 Business quality remains relevant
Fundamentals remain relevant. Check growth, profitability, cash flow and balance sheet quality.
⚠️ Key risk remains
losing 47.80 would weaken the current structure.
Full Analysis Workspace
Technical Signal
Waiting for Confirmation
▲
No confirmed breakout yet. Watch the next level and momentum behavior.
RSI(14)
61.2
Price Chart
ELVN — 1D Chart
Open Full Workspace
Business Lens
Financial context is mixed
Financial conditions require selective monitoring.
↗
Revenue Growth
Insufficient
●
Profitability
Insufficient
≈
Cash Flow
Pressured
⚖
Balance Sheet
Strong
📈 Net Income
-23.63M
≈ Insufficient
🧮 EPS (Basic)
-0.38
≈ Insufficient
Enliven Therapeutics, Inc.
Related Opportunities